Govt expands free hepatitis C screening and treatment programme to GB, AJK

The programme provides hepatitis C screening and treatment without charge. Its expansion matters because people in remote or underserved regions may face greater difficulty reaching specialist care. Early access can help identify infections before serious liver damage develops.

The newly included areas are Gilgit-Baltistan, commonly shortened to GB, and Azad Jammu and Kashmir, or AJK. The programme is described as a government initiative and is linked with the prime minister’s national hepatitis C programme. Other reports also describe screening camps under the same effort.

The supplied article titles do not give the programme’s budget, coverage target, or rollout timetable. Still, including GB and AJK broadens the programme’s geographic reach. It may allow more residents to be tested, confirmed, and treated locally, while helping health authorities understand infections in previously underserved communities.

Hepatitis C is an infection caused by the hepatitis C virus, or HCV. It primarily affects liver cells. Some infections clear naturally, but many become chronic. Chronic infection matters because ongoing inflammation and viral injury can gradually replace healthy liver tissue with scar tissue.

A person may feel well while this damage develops. Over time, scarring can become cirrhosis, which disrupts the liver’s normal work. Advanced disease can lead to liver failure or liver cancer. The risk is higher when infection remains undiagnosed and untreated for many years.

The supplied article titles identify hepatitis C as a national crisis but do not describe its biology or complications. These medical details come from established health knowledge. Effective antiviral medicines can usually eliminate HCV, so finding infection early is important. Treatment before advanced scarring offers the best chance of preventing severe liver consequences.

Pakistan has one of the world’s largest hepatitis C burdens. The World Health Organization’s recent estimates put chronic hepatitis C infections in Pakistan at roughly 8.8 million, while older national estimates have often been higher. The exact number depends on the year, testing method, and definition used.

This burden is substantial beside other major infectious diseases in Pakistan. However, the supplied article titles do not state a precise ranking, percentage, or comparison with tuberculosis, malaria, or other health problems. It would therefore be misleading to assign a specific comparative figure to the article.

The scale explains the focus on free screening and treatment. Large numbers of undiagnosed infections can continue spreading through unsafe blood exposure or medical procedures. Expanding services to GB and AJK could improve case finding, but measuring progress requires reliable testing, treatment records, and updated national estimates.

Screening is important because hepatitis C commonly develops without obvious symptoms. A person can carry the virus while feeling healthy and unknowingly pass it through blood exposure. Meanwhile, liver inflammation and scarring may continue silently. By the time symptoms appear, damage can already be advanced.

Testing usually begins with an antibody test, which shows whether someone has encountered HCV. A follow-up RNA test confirms whether the virus is currently present. This two-step approach distinguishes past exposure from active infection and directs people with active infection toward treatment.

The supplied headlines emphasize free screening camps and expanded services, but do not provide testing numbers or symptom data. In practice, broader screening can uncover hidden infections, connect patients with antiviral care, and reduce future transmission. It also helps health services identify communities where prevention and safe medical practices need greater attention.

Hepatitis C is mainly blood-borne. Transmission occurs when infected blood enters another person’s bloodstream. The virus is not normally spread by hugging, sharing food, coughing, or ordinary household contact. This makes safe healthcare and blood services central to prevention.

Risk rises when needles, syringes, or other instruments are reused without proper sterilisation. Unsafe injections, inadequately screened blood transfusions, and shared equipment for injecting drugs can transmit HCV. Unregulated tattooing or piercing may also pose a risk when instruments are contaminated. Infection can occasionally pass from mother to baby or through sexual contact, though these routes are less common.

The supplied article titles do not list transmission routes or specific unsafe practices. These points come from established medical guidance. Screening identifies people who may need treatment, while infection-control measures prevent new exposures. Together, safer care and diagnosis reduce the cycle of transmission.

A positive antibody screening result does not by itself prove that the virus is still present. Health workers should arrange an HCV RNA test to confirm active infection. People with confirmed infection then receive clinical assessment, including checks for liver damage and other health concerns, before starting treatment.

Modern direct-acting antiviral medicines target steps in the virus’s life cycle. They are taken for a short course and cure more than 95 percent of patients in many settings. Clearing the virus prevents continuing injury, lowering the chance of cirrhosis and liver cancer. It also removes the person’s active source of HCV transmission.

The supplied headlines announce free screening and treatment but do not state drug names, cure rates, or follow-up procedures. Treatment cannot always reverse advanced scarring, so earlier care is better. Patients may still need liver monitoring after cure, especially when cirrhosis has already developed.

Extending free services to GB and AJK matters because geography, travel costs, and limited specialist access can delay testing and treatment. People who cannot easily reach large hospitals may otherwise remain undiagnosed. Local screening reduces one practical barrier and brings the national response closer to communities.

The programme can work through screening camps and linked treatment services. A person is tested, receives confirmatory assessment if needed, and is connected with antiviral medicine. Health workers can also reinforce safe injection, blood, and equipment practices. Each diagnosed and cured infection reduces the pool of people who can transmit HCV.

The supplied headlines specifically identify GB and AJK as newly included, and mention a screening camp at NSU and the National Assembly Secretariat. They do not provide attendance or treatment totals. Success will depend on sustained funding, reliable follow-up, quality testing, and reaching people beyond initial camps.